Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy
Although glucocorticosteroids (GS) and mesalazine are effective and widely employed to treat moderate-to-severe ulcerative colitis (UC), information regarding the factors responsible for response to such therapy is still scarce. One of these factors is thought to be an increased number of mucosal eosinophils. The aim of our study was to determine whether the presence of hypereosinophilia in colonic mucosa of UC patients might influence the short-term response to l treatment with GS and mesasalazine.
Clinical, endoscopic, and pathologic data from patients with a recent diagnosis of moderate UC, who had not undergone treatment, were obtained, and the short-term outcome after 1 month of conventional first-line treatment (mesalazine plus GS) was evaluated.
There were 53 patients with a median age of 37 years (95% CI 30–47).Overall, at the end of treatment period 16 (30%) patients responded, whereas a response was not observed in the other 37 (70%) patients. Interestingly, all patients of this latter group had colonic mucosal hypereosinophilia. No significant differences were found between the two groups concerning sex and age at diagnosis, but hypereosinophilia was inversely correlated with the duration of the disease (p = 0.054), and significantly correlated to the localization of UC (p = 0.0023). In addition, The Mayo score was significantly higher in patients with hypereosinophilia (median 8; 95% CI 8–9;) when compared to patients without hypereosinophilia (median 7; 95% CI 7–7, p < 0.0001) including the Mayo endoscopic subscore (median 3; 95% CI 2–3 vs median 2; 95% CI 2–2, respectively; p = 0.007).
The presence of colonic mucosal hypereosinophilia may be useful to predict the short-term outcome to conventional first-line therapy in treatment-naïve UC patients. It remains to be seen whether this might be important in modifying the first-line therapy in this subgroup of patients.
KeywordsEosinophils Outcome Intestinal Mucosa Ulcerative colitis Treatment
Compliance with ethical standards
Conflict of interest
Authors declares that they have no conflicts of interest.
Since this was a retrospective study, no patient identification was needed, clinical and pathologic data were completely anonymized and no study-driven clinical intervention was performed. Therefore, our Institutional Review Board waived formal review and approval, deeming the study to be an extension of the existing procedures.
For this type of study, formal consent is not required.
- 3.Canavese G, Villanacci V, Antonelli E, Cadei M, Sapino A, Rocca R, Daperno M, Suriani R, Di Santo MG, Cassoni P, Bernardini N, Bassotti G (2017) Eosinophilia-associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. APMIS 125:179–183CrossRefGoogle Scholar
- 9.Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R (2004) Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 53:1806–1812CrossRefGoogle Scholar
- 10.Zezos P, Patsiaoura K, Nakos A, Mpoumponaris A, Vassiliadis T, Giouleme O, Pitiakoudis M, Kouklakis G, Evgenidis N (2014) Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy. Colorectal Dis 16:O420–O430CrossRefGoogle Scholar
- 16.Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476CrossRefGoogle Scholar
- 20.Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R, European Society of Pathology (ESP); European Crohn’s and Colitis Organisation (ECCO) (2013) European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7:827–851CrossRefGoogle Scholar
- 22.Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) (2017) Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Dig Liver Dis 49:604–617CrossRefGoogle Scholar
- 25.Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA (2017) Glucocorticosteroid therapy in inflammatory bowel diseases: from clinical practice to molecular biology. World J Gastroenterol 23:6628–6638CrossRefGoogle Scholar
- 26.Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T (2018) Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 53:305–353CrossRefGoogle Scholar
- 36.Wallon C, Persborn M, Jönsson M, Wang A, Phan V, Lampinen M, Vicario M, Santos J, Sherman PM, Carlson M, Ericson AC, McKay DM, Söderholm JD (2011) Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 140:1597–1607CrossRefGoogle Scholar
- 38.Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, Uike N, Niiro H, Takenaka K, Nagafuji K, Miyamoto T, Harada M, Takatsu K, Akashi K (2009) Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med 206:183–193CrossRefGoogle Scholar
- 41.Coburn LA, Horst SN, Chaturvedi R, Brown CT, Allaman MM, Scull BP, Singh K, Piazuelo MB, Chitnavis MV, Hodges ME, Rosen MJ, Williams CS, Slaughter JC, Beaulieu DB, Schwartz DA, Wilson KT (2013) High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis. PLoS One 8:e82300CrossRefGoogle Scholar